Trials / Completed
CompletedNCT01121770
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fondaparinux sodium injection | 1.5mg subcutaneously every day |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2012-10-01
- Completion
- 2013-02-01
- First posted
- 2010-05-12
- Last updated
- 2014-09-01
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01121770. Inclusion in this directory is not an endorsement.